CCCathy S. Cutler

Cathy S. Cutler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cathy S. Cutler has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 September 2015
      • Vol. 59  (3) , 239-40

    Radiopharmacology: recent developments in the field of radiopharmaceuticals.

    by C S Cutler

  • The use of 111Ag as a tool for studying biological distribution of silver-based antimicrobials

    by Tolulope A. Aweda, Oluwatayo Ikotun, Tara Mastren, Carolyn L. Cannon, Brian Wright, Wiley J. Youngs, Cathy Cutler, James Guthrie, Suzanne E. Lapi

    Recently, there has been an emergence of significant interest in silver-based antimicrobials. Our goal was to develop a radioactive tracer for investigating the biological fate of such compounds. Purified 111Ag was incorporated into the methylated caffeine analogue, IC1 to yield the silver carbene complex designated as [111Ag]SCC1 and investigated in biodistribution studies.


  • Nanoparticles and Phage Display Selected Peptides for Imaging and Therapy of Cancer

    by Cathy S. Cutler, Nripen Chanda, Ravi Shukla, Nebiat Sisay, Melchor Cantorias, Ajit Zambre, Mark McLaughlin, James Kelsey, Anandhi Upenandran, Dave Robertson, et al.

    Molecular imaging probes are a special class of pharmaceuticals that target specific biochemical signatures associated with disease and allow for noninvasive imaging on the molecular level. Because changes in biochemistry occur before diseases reach an advanced stage, molecular imaging probes make it possible to locate and stage disease, track the effectiveness of drugs, treat disease, monitor response, and select patients to allow for more personalized diagnosis and treatment of disease. Targeting agents radiolabeled with positron emitters are of interest due to their ability to quantitatively measure biodistribution and receptor expression to allow for optimal dose determinations. 68Ga is a positron emitter, which allows for quantitative imaging through positron emission chromatography (PET). The availability of 68Ga from a generator and its ability to form stable complexes with a variety of chelates hold promise for expanding PET utilization to facilities unable to afford their own cyclotron. Nanoparticles conjugated with various proteins and peptides derived from phage display that can be selectively targeted are being developed and evaluated for guided imaging and therapy. Herein we highlight some initial efforts in combining the enhanced selectivity of nanoparticles and peptides with 68Ga for use as molecular imaging probes.


  • Laminin receptor specific therapeutic gold nanoparticles ( 198 AuNP-EGCg) show efficacy in treating prostate cancer

    by Ravi Shukla, Nripen Chanda, Ajit Zambre, Anandhi Upendran, Kavita Katti, Rajesh R. Kulkarni, Satish Kumar Nune, Stan W. Casteel, Charles Jeffrey Smith, Jatin Vimal, et al.

    Systemic delivery of therapeutic agents to solid tumors is hindered by vascular and interstitial barriers. We hypothesized that prostate tumor specific epigallocatechin-gallate (EGCg) functionalized radioactive gold nanoparticles, when delivered intratumorally (IT), would circumvent transport barriers, resulting in targeted delivery of therapeutic payloads. The results described herein support our hypothesis. We report the development of inherently therapeutic gold nanoparticles derived from the Au-198 isotope; the range of the 198 Au β-particle (approximately 11 mm in tissue or approximately 1100 cell diameters) is sufficiently long to provide cross-fire effects of a radiation dose delivered to cells within the prostate gland and short enough to minimize the radiation dose to critical tissues near the periphery of the capsule. The formulation of biocompatible 198 AuNPs utilizes the redox chemistry of prostate tumor specific phytochemical EGCg as it converts gold salt into gold nanoparticles and also selectively binds with excellent affinity to Laminin67R receptors, which are over expressed in prostate tumor cells. Pharmacokinetic studies in PC-3 xenograft SCID mice showed approximately 72% retention of 198 AuNP-EGCg in tumors 24 h after intratumoral administration. Therapeutic studies showed 80% reduction of tumor volumes after 28 d demonstrating significant inhibition of tumor growth compared to controls. This innovative nanotechnological approach serves as a basis for designing biocompatible target specific antineoplastic agents. This novel intratumorally injectable 198 AuNP-EGCg nanotherapeutic agent may provide significant advances in oncology for use as an effective treatment for prostate and other solid tumors.


    • 1 August 2009
      • Vol. 53  (4) , 357-8

    Advances in radiopharmacology and radiopharmacy: lions, tigers and bears oh my! Foreword.

    by C S Cutler, S Schwarz

  • Current and Potential Therapeutic Uses of Lanthanide Radioisotopes

    by Cathy S. Cutler, C. Jeffrey Smith, Gary J. Ehrhardt, Tammy T. Tyler, Silvia S. Jurisson, Edward Deutsch

    In the last 25 years, diagnostic nuclear medicine has come to depend on the versatile chemistry of a single radioisotope, technetium-99m (Tc-99m). Different chelating molecules can be used to guide Tc-99m through various physiological pathways in the body to gain information about disease states. No single radioisotope similarly dominates therapeutic applications. In the field of radioisotope therapy, much discussion and debate have focused on what radioisotope might be "ideal" for treatment of malignant tumors. The ideal may not be a single radioisotope, but rather the class of very closely related radiolanthanides and lanthanidelike radioisotopes. These radioisotopes possess strikingly similar chemistries and thus all may be conjugated to biomolecules using a single chelate, the DOTA moiety (and its chemical analogs). They also provide a wide range of physical characteristics, such as half-lives and beta energies, that can be chosen to match the biological properties of the conjugated biomolecule and the malignant tumor. Thus, the radiolanthanide-DOTA bioconjugate model provides a set of physically diverse, but chemically very similar, therapeutic radiopharmaceutical agents, the individual members of which can be tailored to treat specific types of cancers.